BioSpace News Archive

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that Curis management will participate in virtual fireside chats and panels at the following upcoming conferences in November and December.

Axcella Therapeutics today announced two upcoming poster presentations at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually November 12-15, 2021.

MorphoSys AG today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to 18.6 million (US$ 22 million) for the third quarter of 2021 and 46.4 million (US$ 55.5 million) for the first nine months of 2021.

Hologic, Inc., a global leader in women’s health, will launch the NovaSure® V5 global endometrial ablation device at the American Association of Gynecologic Laparoscopists 50th Global Congress on.

LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter 2021 financial results on Wednesday, November 10, 2021

IVERIC bio, Inc. reported that on November 1, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.

Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including SARS-CoV-2, and cancer.

The unique achievements gathered through monoclonal antibody market led to the identification of novel wave of antibody market classified as Bispecific cancer antibody market.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its third quarter 2021 financial results after the close of market on Monday, November 8, 2021.

Amsterdam, the Netherlands – Royal Philips, a global leader in health technology, announced North American availability of new innovations in its portfolio of cardiology solutions designed to seamlessly work together, strengthen clinical confidence, build efficiency throughout the care pathway, and improve cardiac care outcomes and experiences.